Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (5016)	12/5/1997 8:03:00 PM
From: Starlight	Respond to of 17367

M. Murphy will be the speaker at the San D. AAII meeting in January, and I plan to ask him about his thoughts on Xoma. I'm the new incoming president of the local chapter, so I plan to arrange the seating at the dinner table.<g> Betty

To: Arthur Radley who wrote (5016)	12/9/1997 9:28:00 AM
From: Edward Paule	Read Replies (2) \| Respond to of 17367

My copy of Worth arrived yesterday. McCamant's picks for 1998 are ICOS and NeXstar. ICOS up over $2 yesterday; coincidence? Murphy's picks are Integrated Device Technology and Arris. Too bad Murphy didn't pick XOMA. Results of 1997 picks: McCamant had picked Chiron (-14.0%) and XOMA (+91.2%). McCamant's quote on these stocks, "I continue to hold Xoma. The stock should move in 1998 on the progress of its lead drug candidate, Neuprex. With product approvals likely to drive suprise earnings increases for Chiron, we're raising our buy limit to $25." Bummer, IMO saying XOMA is a "hold" is the same as saying "sell some". Saying "we're raising our buy limit on Chiron to $25" is an absolute lie! Last December, when the 1997 special issue of Worth came out, McCamant had a buy limit on Chiron of $30. On 3/20/97, McCamant reduced his buy limit to $25. McCamant has maintained that $25 limit ever since. He's never lowered it below $25, so how can he "raise it" to $25. It sounds like some cheap marketing ploy. Basically, I'm beginning to have doubts about McCamant.